Kymera Therapeutics

Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology

Data to be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II Cambridge, Mass. (June 11, 2020) – Kymera Therapeutics, Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients,